HTA of genetic testing for susceptibility to venous thromboembolism in Italiy

Stefania Boccia, Maria Luisa Di Pietro, Gualtiero Ricciardi, Lamberto Manzoli, Benedetto Simone, S Betti, A Boccia, C Casella, D Coviello, E Di Maria, E Giorgio, M. R. Gualano, G Ivaldi, A Izzotti, C Marzuillo, A Melegaro, A Miani, R Tarricone, A. A. Teleman, V UlianaM Vercelli, P Villari, T. Za

Risultato della ricerca: Working paper

Abstract

Health Technology Assessment (HTA) is important to address the health policy decisions and to make the translational process possible. HTA is a multidisciplinary method that systematically examines the epidemiological, medical, economic, organizational, social and ethical implications of the application of a health technology – usually a drug, medical device or clinical/surgical procedure. This HTA report aims to assess the current scenario of genetic testing provided for the susceptibility to VTE in Italy. The project is based on the ACCE (Analytic validity, Clinical validity, Clinical utility, Ethical, legal and social aspects) model, which was developed by the National Office of Public Health Genomics, CDC in 2004. By using a comprehensive approach, the report considered all the possible implications related to the utilization of genetic testing for the susceptibility to VTE.
Lingua originaleEnglish
Numero di pagine72
Stato di pubblicazionePubblicato - 2012

Keywords

  • HTA
  • Italy
  • genetic testing
  • venous thromboembolism

Fingerprint Entra nei temi di ricerca di 'HTA of genetic testing for susceptibility to venous thromboembolism in Italiy'. Insieme formano una fingerprint unica.

Cita questo